ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 6

Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

, , , ,

This episode discusses the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted targeted treatments, comparing the clinical benefits of a targeted ADC approach vs chemotherapy, with a focus on the TROPION-Lung01 study of Dato-DXd vs docetaxel for heavily pretreated advanced/metastatic NSCLC with actionable genomic alterations.

Video content above is prompted by the following:

  • Please briefly discuss the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted available, targeted therapies.
  • What are the clinical benefits of a targeted ADC approach vs chemotherapy for heavily pretreated advanced/metastatic NSCLC?